|
|
Inflammasome-mediated caspase-1 activity
Gatekeeper of inflammation in the adipose tissue
|
|
|
|
Obesity promotes the development of insulin resistance and type 2 diabetes
|
|
|
|
Obesity, the adipose tissue and type 2 diabetes
|
|
|
|
Adipose tissue as an endocrine organ
secretion of a wide variety of ‘adipokines’
|
|
|
|
Adipose tissue inflammation
|
|
|
|
The pro-inflammatory cytokine IL-1β and Type 2 Diabetes
Current knowledge
|
|
|
|
The NLRP3-inflammasome controls IL-1β release
|
|
|
|
Is caspase-1 present in adipose tissue and regulated during obesity ?
|
|
|
|
Caspase-1 activation in adipose tissue is accompanied by increased levels of IL-1β
|
|
|
|
High fat diet-induced obesity in caspase-1-/- animals
|
|
|
|
Adipose tissue inflammation in HFD-fed wild-type and caspase-1-/- animals
|
|
|
|
Improvement in systemic insulin sensitivity in the absence of caspase-1 ?
|
|
|
|
Inhibition of caspase-1 in obese and insulin resistant animals ?
|
|
|
|
Insulin sensitivity is robustly improved in Ob/Ob animals
after 2 weeks of caspase-1 inhibition
|
|
|
|
The inflammasome and caspase-1 in human adipose tissue
|
|
|
|
IL-1β secretion by human VAT vs. SAT ?
|
|
|
|
Inhibition of caspase-1 specifically inhibits IL-1β production by VAT
|
|
|
|
Summary
|
|
|
|
Future perspective
Identification of potential triggers of inflammasome activation
|
|
|
|
Conclusion
|
|
Deel deze pagina met collega's en vrienden: